ATS (ATS) Q3 2026: Energy Backlog Jumps 87% as Services, Nuclear, and Life Sciences Diversify Growth
ATS’s Q3 revealed a decisive pivot toward higher-margin services and energy diversification, with a record nuclear backlog and strong life sciences execution offsetting transportation softness. Leadership transition sharpened the focus on margin expansion, asset efficiency, and disciplined capital deployment, signaling a more targeted growth approach. Guidance points to stable revenue and ongoing operational leverage, as ATS leans into recurring services and innovation-driven end markets.
Summary
- Energy and Services Mix Shift: Nuclear backlog surged and services revenue benefited from refurbishment work.
- Margin Expansion Mandate: New CEO prioritizes lean execution and recurring aftermarket business.
- Capital Allocation Discipline: M&A focus and operational reinvestment to drive long-term shareholder value.
Business Overview
ATS is a global automation solutions provider, designing and building custom automation, process, and assembly systems for industries including life sciences, energy, food and beverage, consumer products, and transportation. Revenue is generated from project-based automation systems, recurring services, and aftermarket support, with end markets balanced across cyclical and secular growth sectors. Major segments include Life Sciences, Energy (notably nuclear), Food & Beverage, Consumer Products, and Transportation.
Performance Analysis
ATS delivered broad-based revenue growth, up nearly 17% year-over-year, driven by organic gains and a strong contribution from services. Life sciences remained the largest vertical, with revenue at $391 million, while energy backlog reached a record $296 million, up 87% YoY, reflecting a pronounced shift toward longer-cycle, service-rich nuclear projects. The company’s order backlog ended at $2.1 billion, with a healthy book-to-bill ratio of 1.06, signaling sustained demand across most sectors except transportation, which continued to lag.
Profitability improved on higher volumes, as adjusted earnings from operations rose over 21% YoY. However, gross margin declined by 111 basis points to 29.6%, primarily due to program mix, with more lower-margin nuclear work offsetting higher-margin verticals. SG&A costs rose on FX and higher personnel expenses, while working capital efficiency improved, moving closer to the sub-15% target. Strong operating cash flow and disciplined CapEx underpinned a stable financial position, with leverage back within target range.
- Life Sciences Anchors Growth: Second-highest quarterly revenue and $1.1 billion backlog, with pipeline diversification beyond GLP-1 auto injectors.
- Energy and Services Drive Recurring Revenue: Refurbishment and life extension projects in nuclear, plus embedded services, bolstered recurring margin streams.
- Transportation Remains a Drag: Order activity and revenue declined as ATS adopts a more selective approach to auto and EV projects.
Overall, the quarter displayed robust execution and a clear move toward higher-quality, less cyclical revenue, even as segment mix and cost inflation created some margin headwinds.
Executive Commentary
"My focus has been on rapidly translating learning into action, particularly around execution discipline, margin performance, and capital allocation. That lean culture is deeply embedded at ATS through the ABM and our focus will only get sharper going forward."
Doug Wright, Chief Executive Officer
"Order bookings were $821 million, up almost 12% sequentially, supported by activity across multiple end markets. Our backlog reflects a well-balanced mix across end markets and geographies."
Ryan McLeod, Chief Financial Officer
Strategic Positioning
1. Margin Expansion and Lean Operating Model
ATS’s new CEO is doubling down on margin expansion, leveraging the company’s ABM (ATS Business Model, lean operating toolkit) to drive productivity, cost reduction, and asset utilization. Efforts include deeper deployment of lean tools, prioritizing high-value commercial actions, and embedding services within business units to enhance recurring margin streams.
2. Recurring Revenue and Services Integration
Embedding the services business into operating units marks a strategic shift, increasing accountability and aligning services as a margin-enhancing, recurring revenue engine. Refurbishment work, asset management, and aftermarket support are now core to each segment’s solution offering, smoothing earnings volatility and deepening customer relationships.
3. Capital Allocation and M&A Discipline
With leverage back within target range, ATS is signaling a more active M&A stance, but with strict discipline. Management is focused on acquiring capabilities that reinforce core markets, expand recurring revenue, and are accretive to margins. The company continues to cultivate long-term relationships with innovators and founders, seeking bolt-on acquisitions that fit the existing portfolio.
4. End Market Diversification and Innovation
ATS is intentionally diversifying beyond legacy concentration in transportation and GLP-1 auto injectors, expanding into radiopharma, oncology, and nuclear energy. The pipeline now reflects a richer mix of emerging life sciences and energy applications, with innovation and R&D investment targeting technology-driven, higher-margin opportunities.
5. Asset and Working Capital Efficiency
Operational discipline on working capital is yielding results, with the ratio trending toward the sub-15% target. Improved milestone payment timing and tighter asset management are freeing up cash for reinvestment, supporting both organic and inorganic growth.
Key Considerations
This quarter marks a strategic inflection for ATS, as the company pivots toward higher-margin, recurring business and targets operational discipline under new leadership. Investors should track how this transition translates into sustainable earnings power and capital returns.
Key Considerations:
- Margin Levers in Focus: CEO is prioritizing lean execution, commercial discipline, and services mix to drive margin gains.
- Energy and Life Sciences Outperformance: Record energy backlog and expanding life sciences pipeline diversify revenue and reduce cyclicality.
- Transportation Recalibration: ATS is de-emphasizing mega-projects in transportation, focusing on targeted, niche opportunities with better risk-adjusted returns.
- Restructuring and Reinvestment: Increased restructuring spend will be reinvested in innovation and growth areas, with payback expected in fiscal 2027.
- Capital Deployment Optionality: Balance sheet flexibility enables disciplined M&A, with a focus on recurring margin accretion and technology add-ons.
Risks
ATS faces ongoing macro and geopolitical uncertainty, especially around trade, tariffs, and regulatory changes that could impact global automation demand. While management reports no material tariff impact due to USMCA coverage, exposure to long-cycle nuclear and life sciences projects introduces execution and regulatory risks, particularly as new technologies and geographies are targeted. Transportation remains structurally challenged, and any further weakness could pressure topline growth or dilute segment profitability.
Forward Outlook
For Q4 2026, ATS guided to:
- Revenue of $710 million to $750 million
For full-year 2026, management maintained guidance:
- High single-digit revenue growth
Management highlighted several factors that will shape the outlook:
- Continued margin expansion focus through lean and commercial discipline
- Healthy, diversified backlog across life sciences, energy, and consumer products
- Restructuring payback and reinvestment timing to benefit fiscal 2027 operating leverage
Takeaways
ATS’s Q3 underscores a clear evolution toward higher-quality, recurring revenue and margin discipline, with a new CEO steering the company to operational rigor and targeted growth. The record energy backlog and services integration are tilting the business mix, while transportation is being managed for risk and selectivity.
- Pivot to Margin Quality: Leadership is embedding recurring services and lean rigor to structurally improve margins and cash flow.
- End Market Diversification: Energy and life sciences growth are offsetting legacy transportation volatility, reducing cyclicality.
- Watch for M&A Execution: Investors should monitor how capital is deployed into accretive, recurring business lines and whether restructuring delivers operational leverage in fiscal 2027 and beyond.
Conclusion
ATS’s Q3 2026 results highlight a business in transition, with a sharpened focus on margin expansion, recurring services, and disciplined capital allocation. The company’s diversified backlog and operational initiatives position it for more resilient, higher-quality growth, though execution and end market dynamics remain key watchpoints.
Industry Read-Through
ATS’s results signal a broader industry shift toward recurring services and end market diversification in automation and industrial technology. The pivot to nuclear refurbishment and energy life extension reflects a secular trend toward infrastructure renewal and decarbonization, while the expansion in life sciences and radiopharma highlights automation’s role in healthcare innovation. Competitors and peers may face similar margin and mix pressures, especially as transportation and EV mega-project risk is reassessed. Investors should expect continued focus on lean execution, asset efficiency, and recurring revenue models across the industrial automation sector.